Global Radiopharmaceutical Theranostics Market Overview:
The Radiopharmaceutical Theranostics Market Size was estimated at 9.14 (USD Billion) in 2022. The Radiopharmaceutical Theranostics Market Industry is expected to grow from 10.18(USD Billion) in 2023 to 26.71 (USD Billion) by 2032. The Radiopharmaceutical Theranostics Market CAGR (growth rate) is expected to be around 11.31% during the forecast period (2024 - 2032).
Key Radiopharmaceutical Theranostics Market Trends Highlighted
Key market drivers for radiopharmaceutical theranostics include the increasing prevalence of cancer and other diseases, rising demand for personalized medicine, and technological advancements. Opportunities for growth lie in the exploration of new theranostic agents, targeting unmet medical needs, and expanding into emerging markets.Recent trends in radiopharmaceutical theranostics include the development of targeted radiopharmaceuticals, the integration of artificial intelligence and machine learning, and the increasing adoption of theranostics in clinical practice. These advancements are expected to improve the accuracy, efficacy, and accessibility of radiopharmaceutical theranostics in the future.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Radiopharmaceutical Theranostics Market Drivers
Rising Prevalence of Chronic Diseases
One of the key drivers of the Global Radiopharmaceutical Theranostics Market Industry is the increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases. With the population aging and living longer, it is likely that the incidence of such diseases will continue to increase in the future. As a result, the market for radiopharmaceutical theranostics will also grow, as they can be used to diagnose and treat such diseases. They have several key features that make them preferred to traditional medical imaging and treatment methods.First, they can be used to locate and follow the movement of specific cells and tissues in the body. They are also able to detect very small amounts of these and can identify their precise location. Moreover, they can also be used to concentrate in a certain area so as to deliver a dose of radiation for therapeutic or research purposes. That being said, radiopharmaceutical theranostics are used increasingly to manage various chronic diseases.
Technological Advancements
Technological advancements are driving the Global Radiopharmaceutical Theranostics Market Industry. The technological advancements include the development of new radiopharmaceuticals, new imaging techniques, and new delivery systems. These advancements are making radiopharmaceutical theranostics more effective, more convenient, and more accessible. For example, the development of new radiopharmaceuticals with improved targeting capabilities makes it possible to diagnose and treat diseases more precisely.The development of new imaging techniques, such as PET/CT and SPECT/CT, makes it possible to get more detailed images of the body, which can help to improve diagnosis and treatment planning. The development of new delivery systems, such as nanocarriers and liposomes, makes it possible to deliver radiopharmaceuticals to particular cells and tissues more efficiently.
Government Support
Government support is another key driver of the global radiopharmaceutical theranostics market industry. Across the globe, governmental bodies are gradually acknowledging the potential of radiopharmaceutical theranostics for improving patient care and reducing healthcare costs. Thus, they provide funds for research and development, as well as implement policies to support the use of radiopharmaceutical theranostics in practice.
For example, the U.S. Government has provided funds for the development of new radiopharmaceuticals and imaging technologies through the National Institutes of Health. The European Union ensconced its support for radiopharmaceutical theranostics within the Horizon 2020 program, a rather massive research and innovation program designed to last from 2014 to 2020.
Radiopharmaceutical Theranostics Market Segment Insights:
Radiopharmaceutical Theranostics Market Application Insights
The Global Radiopharmaceutical Theranostics Market is segmented by application and major segments include oncology, cardiology, neurology and endocrinology. The largest share of the market is attributed to the increasing number of cancer cases, as well as a growing need for personal and targeted treatment. Another segment, cardiology, is expected to experience substantial growth in the radiopharmaceutical theranostics market in the period of 2023-2032. Such growth is associated with the rapidly increasing incidence of cardiovascular conditions as well as a growing number of theranostics procedures for determining the severity of diseases and the most appropriate medication.Another segment, neurology, is predicted to grow at a decent pace, with an increasing number of new theranostics at an early detection development stage. Additionally, the need for theranostics is growing exponentially, as the number of people with neurological conditions is also on the rise now. The last segment, cardiology, is also expected to experience regular growth, with the growing use of theranostics in the management of endocrine-related conditions, such as diabetes and thyroid issues. Future growth will be facilitated by a better understanding of theranostics and an increased awareness of the need for personalized treatment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Radiopharmaceutical Theranostics Market Radioisotope Insights
Radioisotope Segment Insights and Overview The radioisotope segment of the global radiopharmaceutical theranostics market is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and the development of new radioisotope-based therapies. Among the key radioisotopes used in theranostics, Fluorine-18 (18F), Carbon-11 (11C), Nitrogen-13 (13N) and Gallium-68 (68Ga) hold significant market share. Fluorine-18 (18F): 18F is the most widely used radioisotope in theranostics due to its short half-life (110 minutes) and versatile chemistry, allowing for the synthesis of a wide range of radiopharmaceuticals.It is commonly used in positron emission tomography (PET) imaging for cancer diagnosis and staging. Carbon-11 (11C): 11C has a short half-life of 20 minutes, making it suitable for imaging applications where rapid clearance is desired. It is primarily used in PET imaging for neurology and cardiology applications, including the assessment of cerebral blood flow and myocardial perfusion. Nitrogen-13 (13N): 13N has a half-life of 10 minutes and is commonly used in PET imaging for the assessment of lung function and ventilation. It is also used in the development of radiopharmaceuticals for cancer therapy.Gallium-68 (68Ga): 68Ga has a half-life of 68 minutes and is widely used in PET imaging for the detection and localization of tumors, as well as in the development of theranostic radiopharmaceuticals for targeted cancer therapy. The growth of the radioisotope segment is attributed to the increasing adoption of theranostic approaches in various therapeutic areas, including oncology, neurology, and cardiology. The development of new radioisotope-based therapies, such as targeted alpha therapy (TAT) and radionuclide therapy, is also driving the demand for radioisotopes in the theranostics market.
Radiopharmaceutical Theranostics Market Modality Insights
The Modality segment of the Global Radiopharmaceutical Theranostics Market is expected to witness significant growth over the forecast period. PET (Positron Emission Tomography) is projected to hold a dominant share of the market owing to its wide applications in oncology, cardiology and neurology. The increasing adoption of PET/CT (Positron Emission Tomography/Computed Tomography) for cancer diagnosis and treatment planning is anticipated to drive the growth of this modality. SPECT (Single-Photon Emission Computed Tomography) is another important modality in the Radiopharmaceutical Theranostics Market.It is commonly used in nuclear medicine procedures such as bone scans, myocardial perfusion imaging, and thyroid imaging. The growing demand for SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography) systems, which combine the capabilities of SPECT and CT, is expected to contribute to the growth of this segment. Overall, the Modality segment of the Global Radiopharmaceutical Theranostics Market is poised for robust growth, driven by the increasing prevalence of chronic diseases, technological advancements, and the growing demand for personalized medicine.
Radiopharmaceutical Theranostics Market Target Disease Insights
Cancer, cardiovascular disease, neurological disorders, and endocrine disorders are the major diseases targeted by radiopharmaceutical theranostics. Cancer is the leading target disease for radiopharmaceutical theranostics, accounting for a significant share of the global market. In 2023, the market for cancer radiopharmaceutical theranostics was valued at USD 5.21 billion and is projected to reach USD 13.85 billion by 2032, growing at a CAGR of 12.3%. The growth is attributed to the rising incidence of cancer, the increasing adoption of personalized medicine, and the development of novel radiopharmaceutical theranostics.Cardiovascular disease is another major target disease for radiopharmaceutical theranostics, with a market size of USD 2.45 billion in 2023 and is projected to reach USD 6.52 billion by 2032, growing at a CAGR of 11.9%. The growth is attributed to the increasing prevalence of cardiovascular disease, the rising demand for non-invasive diagnostic techniques, and the development of new radiopharmaceutical theranostics for cardiovascular diseases. Neurological disorders and endocrine disorders are also significant target diseases for radiopharmaceutical theranostics, with growing markets driven by the increasing prevalence of these diseases and the need for improved diagnostic and therapeutic approaches.
Radiopharmaceutical Theranostics Market Regional Insights
The regional segment is a crucial aspect of the Global Radiopharmaceutical Theranostics Market, offering valuable insights into the market's geographical distribution and growth dynamics. North America leads the market with a significant share, driven by advanced healthcare infrastructure, high adoption of theranostics, and robust research and development activities. Europe follows closely, with a well-established healthcare system and a strong focus on personalized medicine. APAC is projected to witness substantial growth in the coming years, owing to rising healthcare expenditure, increasing awareness of theranostics and government initiatives to improve healthcare access.South America and MEA are expected to contribute to the overall market growth, albeit at a moderate pace, as these regions continue to develop their healthcare systems and invest in theranostic technologies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Radiopharmaceutical Theranostics Market Key Players And Competitive Insights:
In the Radiopharmaceutical Theranostics Market industry, major players have been consistently putting efforts into developing products that can image and treat the cancerous cells of the body. The developed products are aligned to decrease the overall dosage of patients as well as to increase the treatment efficiency. The market is gaining attraction among the target users due to the adoption of new technologies, methods, and approaches to fulfill the unmet needs of the International Journal 2019 patients. The leading players in the Radiopharmaceutical Theranostics Market industry are substantially making investments in the research and development of new products, growing their presence across different regions, and gaining a competitive advantage. The importance of the regulatory bodies and government initiatives is substantially rising which is aligned with providing the appropriate guidelines and motivation for developing and commercializing the Radiopharmaceutical Theranostics Market products. The competitive landscape of the market is also getting fueled up with the new development.Cardinal Health is a world leader that provides products, services, and solutions in the healthcare industry. The company is based in Dublin, Ireland and there are 150 countries where it serves its clients. The comprehensive product portfolio and the distribution network of the company are applied to serve the various stakeholders of the healthcare industry, such as hospitals, clinics, pharmacies, and manufacturers as well as to the customers and patients. The company substantially focuses on innovation and technological advancements, which play a crucial role in enhancing the offering of the company. A detailed analysis states that Cardinal Health is substantially participating in the Radiopharmaceutical Theranostics Market industry by providing various radiopharmaceuticals and related services. The timely and accurate delivery of the products across the healthcare industry is ensured by the distribution network of the company.IBA MolecularIBA Molecular is a worldwide participant in the Radiopharmaceutical Theranostics Market industry. The company is largely focused on the development and production of medical imaging and therapy radiopharmaceuticals. The multi-modality imaging and therapy products and the services of the company meet the needs of thousands of patients every day. The research and development facilities of the company are used to offer the widest range of imaging and therapeutic solutions to patients. Involvements of the leading experts in the industry help to bring advanced products to the market. A similar approach is adopted in the case of Radiopharmaceutical Theranostics Market products.
Key Companies in the Radiopharmaceutical Theranostics Market Include:
-
Toshiba Medical Systems
-
Nordion
-
Radiomedix
-
Lantheus Holdings
-
Mylan
-
Sirtex Medical
-
Cardinal Health
-
IBA
-
GE Healthcare
-
Merck KGaA
-
Philips Healthcare
-
Novartis
-
Bayer
-
Telix Pharmaceuticals
Radiopharmaceutical Theranostics Market Industry Developments
The global radiopharmaceutical theranostics market is expected to reach USD 26.71 billion by 2032, exhibiting a CAGR of 11.31% from 2024 to 2032. The increasing prevalence of chronic diseases, growing demand for personalized medicine, and technological advancements in radiopharmaceutical theranostics are driving market expansion. Asia Pacific is expected to witness significant growth due to rising healthcare expenditure and increasing awareness about theranostics. Recent news developments include Novartis' collaboration with Advanced Accelerator Applications to develop and commercialize 177Lu-PSMA-617 for prostate cancer treatment and Bayer's acquisition of Vividion Therapeutics to strengthen its oncology portfolio with targeted radiopharmaceuticals.
Radiopharmaceutical Theranostics Market Segmentation Insights
-
Radiopharmaceutical Theranostics Market Application Outlook
-
Oncology
-
Cardiology
-
Neurology
-
Endocrinology
-
Radiopharmaceutical Theranostics Market Radioisotope Outlook
-
Fluorine-18 (18F)
-
Carbon-11 (11C)
-
Nitrogen-13 (13N)
-
Gallium-68 (68Ga)
-
Radiopharmaceutical Theranostics Market Modality Outlook
-
PET (Positron Emission Tomography)
-
SPECT (Single-Photon Emission Computed Tomography)
-
SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography)
-
PET/CT (Positron Emission Tomography/Computed Tomography)
-
Radiopharmaceutical Theranostics Market Target Disease Outlook
-
Cancer
-
Cardiovascular Disease
-
Neurological Disorders
-
Endocrine Disorders
-
Radiopharmaceutical Theranostics Market Regional Outlook
-
North America
-
Europe
-
South America
-
Asia Pacific
-
Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
9.14(USD Billion) |
| Market Size 2023 |
10.18(USD Billion) |
| Market Size 2032 |
26.71(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
11.31% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Toshiba Medical Systems, Nordion, Radiomedix, Lantheus Holdings, Mylan, Sirtex Medical, Cardinal Health, IBA, GE Healthcare, Merck KGaA, Philips Healthcare, Novartis, Bayer, Telix Pharmaceuticals |
| Segments Covered |
Application, Radioisotope, Modality, Target Disease, Regional |
| Key Market Opportunities |
Radiotheranostics for Cancer Treatment NonInvasive Disease Diagnosis Alzheimers Management Cardiovascular Imaging Infection Detection |
| Key Market Dynamics |
Growing demand for precision medicine Advancements in radiopharmaceutical technology Increasing prevalence of cancer Government initiatives and funding Technological advancements in imaging and diagnostics. |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global Radiopharmaceutical Theranostics Market is expected to reach a valuation of USD 26.71 billion by 2032, exhibiting a CAGR of 11.31% during the forecast period from 2024 to 2032.
North America is expected to remain the dominant region in the Global Radiopharmaceutical Theranostics Market throughout the forecast period, owing to the strong presence of key market players, advanced healthcare infrastructure, and increasing adoption of theranostic procedures.
The increasing prevalence of chronic diseases, rising demand for personalized medicine, advancements in theranostic technologies, and growing government support for research and development are the primary factors driving the market growth.
The oncology segment is anticipated to hold the largest share in the Global Radiopharmaceutical Theranostics Market due to the high prevalence of cancer and the increasing use of theranostic agents for cancer diagnosis and treatment.
Key competitors in the Global Radiopharmaceutical Theranostics Market include Bayer AG, Cardinal Health, Curium, GE Healthcare, IBA Molecular, Lantheus Holdings, Inc., Merck KGaA, Nordion (Sterigenics), and Siemens Healthineers.
The Asia-Pacific region is projected to witness a significant growth rate in the Global Radiopharmaceutical Theranostics Market, with a CAGR of 12.5% during the forecast period, primarily attributed to the increasing healthcare expenditure, rising awareness about theranostic procedures and growing investments in healthcare infrastructure.
Challenges faced by the Global Radiopharmaceutical Theranostics Market include stringent regulatory requirements, reimbursement issues, limited availability of skilled professionals, and the high cost of theranostic agents.
Technological advancements, such as the development of targeted theranostic agents, personalized medicine approaches, and improved imaging techniques, are positively impacting the Global Radiopharmaceutical Theranostics Market by enhancing the accuracy and efficacy of theranostic procedures.
The future of the Global Radiopharmaceutical Theranostics Market appears promising, driven by the increasing demand for personalized and targeted therapies, advancements in theranostic technologies, and growing government support for research and development.
The competitive landscape of the Global Radiopharmaceutical Theranostics Market is anticipated to intensify in the coming years, with key players focusing on strategic collaborations, acquisitions, and new product development to gain market share and strengthen their positions.
